Covid-19 Update

Jeremy Hunt Excerpts

Monday 6th September 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful to the right hon. Member for his support and his words on the vaccination of pregnant women and the protection that the vaccine offers them.

On the right hon. Member’s question about the JCVI advice on 12 to 15-year-olds, the JCVI looked at the very narrow impact of the vaccine on 12 to 15-year-olds, because that is very much its remit. It also advised that the chief medical officers should take a wider look. That is what they are doing as we speak. Panels of experts from local public health as well as other experts are looking at the impact of the vaccine on mental health and the disruption to education specifically for 12 to 15-year-olds. They will come back with recommendations. The JCVI is observing those panels and is very much in the room, as far as that is concerned.

It is also worth reminding the House that the Medicines and Healthcare Products Regulatory Agency has looked at the Pfizer and Moderna vaccines and has approved both vaccines as safe and eligible to be administered to 12 to 15-year-olds. It is not worth our pre-empting the report of the chief medical officers of England, Wales, Scotland and Northern Ireland. Throughout the pandemic, we have operationalised the vaccine programme; we prepare early and we prepare well. To give the right hon. Member a direct answer to his question, the NHS is prepared to administer a vaccine within five working days of any recommendation. That does not pre-empt any recommendation. We did the same when none of the vaccines was approved. Some colleagues will recall Brigadier Phil Prosser explaining at the press conference that we had built the equivalent of the infrastructure of a national supermarket chain and were growing it by 20% every week. We have done the same thing when it comes to all outcomes of the deliberations at the JCVI and what it will ultimately recommend.

On education, the Secretary of State for Education addressed many of the issues on the mitigation and controls in schools, as well as testing and the very successful adult vaccination programme that we have delivered, which is now also delivering protection for 16 and 17-year-olds.

I really want to address the point about flu and I hope that we can have a sensible discussion on it. We are being very ambitious on flu. The interim advice from the JCVI is wherever possible to co-administer flu and covid vaccines. Traditionally, flu vaccination begins earlier—it begins now. One of the suppliers, Seqirus, has had a border issue with its Spanish fill-and-finish factory, which it has used for many, many years. This is the first time that it has had this issue. It is meeting the Spanish regulator to see what the issue is. It is being very careful and estimating a one or two-week delay. This will not delay the overall flu vaccination programme at all. Its German and Belgian supply chain has been flowing normally. It is one of the suppliers, so I urge the right hon. Gentleman not to, as a knee-jerk reaction, talk about flu vaccine shortages. We are being incredibly ambitious on flu vaccines—including procuring centrally as well as the traditional procurement through GPs and pharmacies—with a big, big programme.

Wherever possible, we will co-administer. The only caveat I would place on that is that the JCVI has given us only its interim advice on covid. We are not yet there with the cov-boost data, which it will look at. It will give us its final advice on covid. If it chooses a vaccine that requires, for example, a 15-minute observation period, we have a very different challenge in co-administration, but nevertheless, wherever possible, we will co-administer. We have made it possible for vaccinated volunteers to administer flu and covid vaccines.

Finally, on funding, I am glad that the right hon. Member agrees that the £5.4 billion announced today is a good thing. I urge him not to speculate on how we will pay for social care and to wait for the announcement; I am sure that we can then discuss it in this place and in the media.

[Jeremy Hunt (South West Surrey) (Con)]

I have great respect for the excellent job that my right hon. Friend is doing. He will know that Israel shows that even a good vaccination programme does not stop the Delta variant driving up hospitalisations. However, Israel also shows that a booster programme brings down those hospitalisations in as little as two weeks. Given that the big lesson from last year is that acting early can stop the need for lockdowns, as happened in Taiwan, Singapore, Korea and a number of other places, is this not a moment for Ministers to say, “Look, we understand that the scientists want to take their time, but we have a reasonable idea of what they are likely to recommend, so we are going to get on with this booster programme before it is too late”?

[Nadhim Zahawi]

I am grateful for my right hon. Friend’s excellent question. I would say two things: first, in many ways, the decision taken by our chief medical officers in England, Wales, Scotland and Northern Ireland to increase the dosing interval, including for the vaccine that Israel uses—the Pfizer vaccine—from three to 12 weeks, with it now at an optimal eight weeks, was actually an inspired and clinically incredibly important decision, because it demonstrates, in real-world data, that the durability of the protection is increased over people who have had two jabs with a three-week dosing period. So we are in a slightly more advantageous position, if I can describe it as such.

My right hon. Friend makes an important point on boosters. The booster programme is probably the most important piece of the jigsaw yet to fall into place before we can transition this virus from pandemic to endemic status. I reassure him and the House that the NHS has all the plans in place to deliver the booster programme in what will, in some weeks, probably break our record, which we set in phase 1 of the vaccination programme. The JCVI has given us its interim advice on who needs to boost. It has added, obviously, the immunosuppressed to categories 1 to 4 and it has rightly recommended that we go big on flu. I am equally worried about that. Flu has been non-existent because of the severe social isolation of lockdowns and a big flu season could be detrimental as well. We are ready to go. As soon as cov-boost reports, which is imminent, we will be able to operationalise a massive booster programme.